pipette
ENEnglish

A PTN-Rich MSC Subtype Promotes Cartilage Repair in End-Stage Knee Osteoarthritis

Z. Wang, L. Yin, F. Zhao, D. Liu, J. Li, J. Chu, Z. Zhou, H. Liu, R. Fan, Z. Yuan, Y. Zhang, L. Liu, G. Yu, M. Sun, B. Shi, J. Han, Y. Zhao

PreprintUso en el mundo real

En palabras de los autores

Mesenchymal stem cell (MSC) therapy for end-stage knee osteoarthritis (KOA) shows inconsistent efficacy, and whether MSCs retain cartilage repair capacity in the inflammatory joint remains unclear. Using single-cell RNA sequencing of human Kellgren-Lawrence grade (G ) and (G ) KOA joint tissues and exogenous MSCs, we found that pleiotrophin (PTN) signalling shifts from MSC-chondrocyte crosstalk to chondrocyte-dominated autocrine signalling, with PTN exhaustion and elevated cluster of differentiation 74 (CD74) in G cartilage. We therefore identified and sorted a PTN-rich CD74-low placenta-derived MSC subtype and evaluated it in a murine KOA model and in co-culture with patient-derived chondrocytes. This subtype enhanced cartilage repair, upregulated SOX9, and suppressed MMP13, CD74, IL-6, and IL-1{beta}, potentially through CD74 suppression and reduced NF-{kappa}B signaling. These findings provide a basis for functionally defined, stage-matched cell therapy tailored to the pathological microenvironment of end-stage KOA.

Resultado principalEl resumen no menciona limitaciones.

Apareció: martes, 10 de noviembre. bioRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.06.764540